14
Participants
Start Date
July 19, 2022
Primary Completion Date
May 31, 2023
Study Completion Date
May 31, 2023
PI-2620 tracer
Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
Lifecourse Epidemiology of Adiposity and Diabetes Center, Aurora
American College of Radiology
OTHER
University of Colorado, Denver
OTHER